| Prostate Cancer |
1 |
1 |
| BRCA |
0 |
0.99 |
| Toxicology |
0 |
0.41 |
| Cancer |
0 |
0.37 |
| Chemotherapy |
0 |
0.98 |
| Prostate Specific Antigen |
0 |
0.37 |
| Tumor |
0 |
0.3 |
| Aminotransferase |
0 |
0.22 |
| Anemia |
0 |
0.15 |
| Clinical Research |
0 |
0.15 |
| Poly ADP-Ribose Polymerase (PARP) Inhibitor |
0 |
0.11 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.07 |
| Connecticut |
0 |
0.07 |
| Costimulation |
0 |
0.07 |
| Europe |
0 |
0.07 |
| Fatigue |
0 |
0.07 |
| HIV Infection |
0 |
0.07 |
| Hormonal Therapy |
0 |
0.07 |
| Nail |
0 |
0.07 |
| Nausea |
0 |
0.07 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.07 |
| T-Lymphocyte |
0 |
0.07 |
| Tissue |
0 |
0.07 |